It is important to publish the results of oncology Phase I studies, not only for the investigators who performed the work – as their academic success is often measured by the number of papers they publish – but also for the parties involved. For example, for the scientific community it is a way to stay up to date with the latest developments in their field, whereas for the public it shows that their money (e.g. taxes and charity) is put to good use. For investors it is an inflection point in value creation and finally for the biotech company it marks a milestone in the development of their product and is a great tool to showcase their product to the rest of the world via social media, press releases and presentations / posters at conferences.
However, in which journal should you publish your oncology Phase I study? In order to give you an idea of your options, SMS-oncology performed a Pubmed search for Phase I or Phase I/II studies that were published in the years 2012 and 2013 in which adult patients with solid tumors were enrolled. We found a total of 663 articles that fulfilled these criteria. These papers were published in 108 different journals (see the table below). The mean number of articles published per journal in those two years was six. However, the actual number of papers published per journal showed a lot of variation. About 46% of the journals only published one paper, whereas one journal (Cancer Chemotherapy and Pharmacology) published a staggering number of 122 papers in two years. The ten journals with the most published oncology Phase I or Phase I/II studies accounted for ~63% of all published studies.
The impact factor of a journal is a measurement reflecting the average number of citations to recent published articles in that journal. A journal with a higher impact factor is deemed to be more important than those with lower ones. We had a look at the impact factor of the journals that published three or more articles describing the results of an oncology Phase I or Phase I/II study in the last two years. The median impact factor was 3,498. Hepatogastroenterology had the lowest impact factor (0,774) and published three studies, whereas the New England Journal of Medicine had the highest impact factor (51,658) and published five studies. There were only three journals that had an impact factor higher than 8, namely Journal of Clinical Oncology (eleven articles), Lancet Oncology (seven articles) and New England Journal of Medicine (five articles).
In summary, there is a wide variety of journals you can choose from for the publication of your oncology Phase I study. Where you will publish your study depends on factors such as indication, treatment modality, study endpoints and study results. At SMS-oncology we are looking forward to see your Phase I oncology study published in the (near) future.